Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where A. Bakshi is active.

Publication


Featured researches published by A. Bakshi.


Cancer | 2007

Primary Diffuse Large B-Cell Lymphoma of the Tonsil Is a Higher Radiotherapy Dose Required?

Siddhartha Laskar; Gaurav Bahl; Mary Ann Muckaden; Reena Nair; Sudeep Gupta; A. Bakshi; Sumeet Gujral; Tanuja Shet; Shyam Kishore Shrivastava; Ketayun A. Dinshaw

The purpose was to evaluate the prognostic factors and treatment outcome of Indian patients with primary diffuse large B‐cell lymphoma (DLBCL) of the tonsil treated at a single institution.


International Journal of Radiation Oncology Biology Physics | 2011

Prognostic Factors and Outcome in Askin-Rosai Tumor: A Review of 104 Patients

Siddhartha Laskar; Nair Cn; Suman Mallik; Gaurav Bahl; Suresh K. Pai; Tanuja Shet; Tejpal Gupta; Brijesh Arora; A. Bakshi; C.S. Pramesh; Rajesh C. Mistry; Sajid S. Qureshi; Seema Medhi; Nirmala A. Jambhekar; Purna Kurkure; Shripad Banavali; Mary Ann Muckaden

PURPOSE To evaluate the prognostic factors and treatment outcome of patients with Askin-Rosai tumor of the chest wall treated at a single institution. METHODS AND MATERIALS Treatment comprised multiagent chemotherapy and local therapy, which was either in the form of surgery alone, radical external-beam radiotherapy (EBRT) alone, or a combination of surgery and EBRT. Thirty-two patients (40%) were treated with all three modalities, 21 (27%) received chemotherapy and radical EBRT, and 19 (24%) underwent chemotherapy followed by surgery only. RESULTS One hundred four consecutive patients aged 3-60 years were treated at the Tata Memorial Hospital from January 1995 to October 2003. Most (70%) were male (male/female ratio, 2.3:1). Asymptomatic swelling (43%) was the most common presenting symptom, and 25% of patients presented with distant metastasis. After a median follow-up of 28 months, local control, disease-free survival, and overall survival rates were 67%, 36%, and 45%, respectively. Median time to relapse was 25 months, and the median survival was 76 months. Multivariate analysis revealed age ≥18 years, poor response to induction chemotherapy, and presence of pleural effusion as indicators of inferior survival. Fifty-six percent of patients with metastatic disease at presentation died within 1 month of diagnosis, with 6-month and 5-year actuarial survival of 14% and 4%, respectively. CONCLUSION Primary tumor size, pleural effusion, response to chemotherapy, and optimal radiotherapy were important prognostic factors influencing outcome. The combination of neoadjuvant chemotherapy, surgery, and radiotherapy resulted in optimal outcome.


Leukemia & Lymphoma | 2006

Primary non-Hodgkin's lymphoma of the nasopharynx: prognostic factors and outcome of 113 Indian patients.

Siddhartha Laskar; Mary Ann Muckaden; Gaurav Bahl; Sandeep De; Reena Nair; Sudeep Gupta; A. Bakshi; Kumar Prabhash; Dipen Maru; Sumeet Gujral; Purvish M. Parikh; Shyam Kishore Shrivastava; Ketayun A. Dinshaw

This single institutional study evaluated the prognostic factors and treatment outcome of 113 Indian patients with primary nasopharyngeal non-Hodgkins lymphoma. At presentation, 28% had stage I and 62% had stage II disease. Treatment comprised of a combination of chemotherapy (CTh) and radiotherapy (RT) in the majority of the patients (76%). After a median follow-up of 56 months, the 5-year disease-free survival (DFS) and overall survival (OS) for the whole group were 55.8% and 57.9%, respectively. Multivariate analysis showed that; age > 30 years [hazard ratio (HR) = 6.59, 95% confidence interval (CI) = 2.59 – 16.7, P < 0.0001], WHO performance score ≥ 2 (HR = 2.34, 95% CI = 1.01 – 5.46, P = 0.050), T-cell lymphomas (HR = 2.81, 95% CI = 1.14 – 6.96, P < 0.001) and the presence of B symptoms (HR = 3.65, 95% CI = 1.77 – 7.53, P = 0.025), had a negative influence on survival. Patients treated with a combination of CTh and RT had a significantly better outcome than those treated with CTh alone (OS: 69%vs. 31%, P < 0.00001). HR for death in the CTh alone group was 3.73 (95% CI = 1.95 – 7.13). The CR (P = 0.01), DFS (P = 0.01) and OS (P = 0.03) rates were significantly better for patients receiving a RT dose of ≥4500 cGy. HR in the subgroup that received a RT dose of <4500 cGy was 2.51 (95% CI = 1.04 – 6.06). These results suggest that combined modality treatment, comprising of CTh and RT (with an RT dose of ≥4500 cGy), results in satisfactory outcome in patients with this rare neoplasm.


Indian Journal of Cancer | 2006

Successful complete regression of isolated intramedullary spinal cord metastases from epithelial ovarian carcinoma with chemotherapy and radiotherapy

A. Bakshi; G. Biswas; C. D. Deshmukh; Narayan Prasad; Reena Nair; Pm Parikh

Advances in the management of ovarian cancer by use of aggressive surgery and effective platinum-based chemotherapy have prolonged survival; this may have resulted in an alteration of the metastatic pattern of the disease and spread to unusual sites (e.g, CNS) has become more common. Also, with the availability of more sensitive imaging techniques, these tumors are being diagnosed with increasing frequency. Intramedullary spinal cord metastasis is rare. We report one such case treated successfully with chemotherapy and radiotherapy with long-term survival.


Medical Oncology | 2004

Primary non-Hodgkin's lymphoma of the bone: a single institution experience.

C. D. Deshmukh; A. Bakshi; Purvish M. Parikh; Reena Nair; V. R. Pai; Sudeep Gupta; A. Shaikh; Mary Ann Muckaden; Kikkeri N. Naresh; Tapan K. Saikia

Primary non-Hodgkin’s lymphoma of the bone is an unusual entity. Twenty-five patients with diffuse large cell lymphoma of the bone were registered at the Tata Memorial Hospital (TMH) from August, 1991, to May, 2002. Pain at the local site and soft tissue swelling were the commonest symptoms. Involvement of the bones in the lower half of the body was more frequent than the bones in the upper half. Osteolytic lesions and an associated soft tissue mass were the common radiological findings. Nineteen patients received CHOP chemotherapy and five received COP chemotherapy. Twenty-three patients received involved field radiotherapy. The overall response to therapy was 96%. On follow-up, two patients had a nodal relapse. One patient died of progressive disease, and one patient died of cryptococcal meningitis. There were no deaths due to treatment-related toxicity. The mean progression free survival was 9.39 yr and the overall survival was 11.66 yr. The median overall survival has not been reached. At last follow-up, 21 patients were being following up at TMH and are free of disease.Conclusion: Primary bone lymphoma is a malignancy that is highly curable with a combination of chemotherapy and radiotherapy.


Journal of Cancer Research and Therapeutics | 2006

Recurrent episodes of hematuria: A rare presentation of leiomyosarcoma of prostate

Kaustav Talapatra; Bhushan Nemade; Ritu Bhutani; Shubhada Kane; A. Bakshi; Mary Ann Muckaden; Siddhartha Laskar

Leiomyosarcoma of the prostate is an extremely rare entity. Sarcomas account for about 1% of all malignant tumors and less than 5% of them arise from the genitourinary tract. Majority of patients present with urinary obstructive symptoms. The outcome is generally poor. Surgery with or without radiotherapy/chemotherapy forms the mainstay of treatment for patients with operable tumors. We report a patient presenting with recurrent episodes of hematuria.


Annals of Oncology | 2010

CD26 expression in donor stem cell harvest and its correlation with engraftment in human haematopoietic stem cell transplantation: potential predictor of early engraftment

Kumar Prabhash; N. Khattry; A. Bakshi; R. Karandikar; Amit Joshi; S. Kannan; P. S. R. K. Sastry; Purvish M. Parikh; J. A. Kode

BACKGROUND The efficiency of haematopoietic stem and progenitor cells (HSPCs) is important when donor cell numbers are limiting. Stable white blood cell (WBC) and platelet engraftment is crucial for the outcome of haematopoietic stem cell transplantation (HSCT). DESIGN This article evaluates CD26/dipeptidyl peptidase-IV expression on mobilised peripheral blood stem cell (PBSC) harvest of donors and its correlation with engraftment in HSCT. We have analysed CD26 expression on cells in various gates, that is, lymphocytes, monocytes, neutrophils and all populations using flow cytometry tool. RESULTS Ours is the first study on human mobilised PBSC harvest from cancer patients or allogeneic related donors (n = 28) to demonstrate that increased CD26 expression leads to early engraftment in transplanted cancer patients. Correlation of CD26 expression with WBC engraftment was statistically significant (lymphocyte gate: P < 0.00001; monocyte gate: P < 0.00001; neutrophil gate: P < 0.00001; all populations: P < 0.00001). CD34 expression is a known predictor of engraftment. Nevertheless, there was no correlation between CD34 and CD26 expression in these cases. CONCLUSIONS This study has given important leads indicating that CD26 expression may be an independent predictor of engraftment. Further study with large number of patients as well as study on circulatory CD26 may add valuable information towards improving current knowledge on CD26.


Journal of Pediatric Hematology Oncology | 2008

Primary PNET of maxilla: an unusual presentation.

Pranshu Mohindra; Bhooshan Zade; Ayan Basu; Nikhilesh Patil; Seethalakshmi Viswanathan; A. Bakshi; Mary Ann Muckaden; Siddhartha Laskar

Primitive neuroectodermal tumors (PNETs) are a type of small round cell tumors developing from migrating embryonal cells of the neural crest. Peripheral primitive neuroectodermal tumors (pPNETs) are less common with varying incidence of occurrence in head and neck region. Only 8 reported cases of primary PNET of maxilla are available in English literature. We report a case of 8-year-old boy diagnosed as pPNET of maxilla after detailed radiologic, histopathologic, including immuno-histochemical examination and molecular diagnosis using reverse transcription-polymerase chain reaction showing EWS-FLI1 translocation. The boy was treated with multiagent combination chemotherapy to be followed by definitive radiation therapy. A brief literature review of diagnosis and management of the previous 8 reported cases is done. In view of no definitive guideline for management of such cases, treatment on the lines of other pPNET is suggested.


Indian Journal of Cancer | 2013

Is there a role for metronomic induction (and maintenance) therapy in elderly patients with acute myeloid leukemia? A literature review.

N Tandon; Shripad Banavali; Hari Menon; Sumit Gujral; Pratibha S. Amare Kadam; A. Bakshi

Acute myeloid leukemia (AML) in older adults differs biologically and clinically from that in younger patients and is characterized by adverse chromosomal abnormalities, stronger intrinsic resistance, and lower tolerance to chemotherapy. In patients over age 60 with AML, cure rates are under 10% despite intensive chemotherapy, and most of them die within a year of diagnosis. Over the last decade, metronomic chemotherapy has emerged as a potential strategy to control advanced/refractory cancer. Here, we report a case of a 68-year-old gentleman having AML with high-risk cytogenetic features, who achieved complete remission on our oral metronomic PrET (PrET: Prednisolone, etoposide, thioguanine) protocol on an outpatient basis. He was later treated with standard high-dose (HD) cytosine arabinoside (Ara-C) consolidation followed by maintenance with etoposide, thioguanine, and sodium valproate. Presently, the patient is nearly 35 months since diagnosis and 21 months off treatment. This case report and review highlights that the combination of oral low-intensity metronomic therapy, followed by standard HD consolidation therapy and metronomic maintenance therapy may be well tolerated by elderly patients especially with less proliferative, high (cytogenetic)-risk AML who are otherwise deemed to be unfit for intensive intravenous induction chemotherapy regimens. References for this review were identified through searches of Pubmed for recent publications on the subject as well as searches of the files of the authors themselves. The final list was generated on the basis of originality and relevance to this review.


Indian Journal of Dermatology, Venereology and Leprology | 2005

Ewing's sarcoma with cutaneous metastasis - a rare entity : Report of three cases

G. Biswas; A Khadwal; P Kulkarni; A. Bakshi; Nair Cn; Purna Kurkure; Maryann Muckaden; Purvish M. Parikh

Ewings sarcoma (ES) is a small round cell tumor, usually arising from flat bones and diaphyseal region of long bones. It is commonly found in the first two decades of life. It is curable when diagnosed in the localized stage and requires multimodality treatment. ES is a chemosensitive tumor. It metastasizes commonly to lung, pleura and other bones. Less common sites of metastasis are lymph nodes, CNS and liver. Skin metastasis is extremely uncommon. It occurs in up to 9% of all patients with cancer. Growth pattern of cutaneous metastasis is unpredictable and may not reflect that of primary tumor. We hereby report three cases of Ewings sarcoma that developed skin metastasis.

Collaboration


Dive into the A. Bakshi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

G. Biswas

Tata Memorial Hospital

View shared research outputs
Top Co-Authors

Avatar

Reena Nair

Tata Memorial Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A. Khadwal

Tata Memorial Hospital

View shared research outputs
Top Co-Authors

Avatar

Gaurav Bahl

Tata Memorial Hospital

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge